Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CytomX Therapeutics, Inc. (CTMX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/24/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
08/08/2023 8-K Quarterly results
Docs: "CytomX Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update - CX-904 initial Phase 1 dose escalation data anticipated first half of 2024 - - IND filings for CX-2051 and CX-801 anticipated in the fourth quarter of 2023 - - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT - SOUTH SAN FRANCISCO, Calif., August 8, 2023 –"
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
06/30/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Form of Pre-Funded Warrant",
"Form of Tranche Warrant",
"Unit Purchase Agreement by and among the Company and the Purchasers"
05/09/2023 8-K Quarterly results
Docs: "CytomX Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - Continued progress in Phase 1 dose escalation for CX-904 - - IND enabling activities on track for filings for CX-2051 and CX-801 in the second half of 2023 - - Bristol Myers Squibb advances Anti-CTLA-4 non-fucosylated Probody®, BMS-986288, from Phase 1 to Phase 2 clinical evaluation as lead, next-generation CTLA-4 program - - CD71strategy under evaluation including potential further advancement of CX-2029 and next generation CD71 targeting strategies - - Continued progress in strategic alliances including a $5 million clinical candidate milestone in Probody® T-Cell Bispecific collaboration with Astellas and initiation of Regeneron and Moderna collaborations - - Marcia Belvin, Ph.D. promoted to C..."
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/27/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/27/2023 8-K Quarterly results
03/27/2023 10-K Annual Report for the period ended December 31, 2022
03/27/2023 10-K/A Annual Report for the period ended December 31, 2021 [amend]
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
02/24/2023 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
02/14/2023 SC 13G/A TANG CAPITAL PARTNERS LP reports a 5.3% stake in CytomX Therapeutics, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 6.9% stake in CytomX Therapeutics Inc.
01/05/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/21/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
11/08/2022 8-K Quarterly results
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
09/23/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
09/13/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
08/04/2022 8-K Quarterly results
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
07/29/2022 SC 13G/A BIOTECHNOLOGY VALUE FUND L P reports a 10.1% stake in CytomX Therapeutics, Inc.
07/25/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/13/2022 8-K Quarterly results
07/08/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
07/06/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
05/05/2022 10-Q Quarterly Report for the period ended March 31, 2022
04/27/2022 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy